Page 6 - Pharma Industry

Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20

Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine altSonflex1-2-3 in collaboration with GSK

NPPA fixes retail prices for 41 drug combinations, including empagliflozin

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments, citing steep price drops and growing generic availability

Zydus signs deal with Agenus for BOT and BAL cancer therapies in India

Zydus Lifesciences has partnered with Agenus to license the cancer immunotherapies Botensilimab and Balstilimab for India and Sri Lanka, expanding its oncology offerings

Sun Pharma halts development of SCD-044 drug after trial disappointment

Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis

Medical representatives barred from govt hospitals to stop pharma influence

The Centre's move seeks to curb the influence of pharmaceutical companies. Sharing of information must now happen through email or other digital platforms

Lupin signs licensing deal with SteinCares for ranibizumab in LatAm

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina

Sun Pharma to invest $25 million in Pharmazz Inc; raises stake to 22.7%

The company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar

Strong growth seen for Divi's Laboratories, but upside capped by valuations

Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range

Sun Pharma gets USFDA approval for new device to treat skin disease

The company says that the new device is more compact and easier to use than its predecessor

JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%

JB Pharma posts strong FY25 performance with 19.3% profit growth; domestic business up 20%, CDMO segment and Russia drive international gains

Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term

US President Donald Trump's drug price slash could sting Indian pharma

Up to 80% US price cuts may squeeze margins, push up innovator drug costs

Trump's 'Make in America' push: Indian drug cos in no rush to make US shift

Pharma industry veteran said that the US wanting to encourage local production is a very natural thing to do

Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr

India branded business grows 8% in Q4FY25 with 4 product launches while Ex-US markets rise 43% and US segment delivers 20% growth during the quarter

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

Indian pharma companies eye larger share of US cancer generics market

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures in the generics space in the US

Trump tariff plan: US Prez to announce levy on pharma imports soon

The pharmaceutical sector was previously spared by the Trump administration in the last round of tariffs that were announced on April 2

Trump tariffs drags Sensex 300pts amid volatility; IT, pharma in focus

While the Nifty IT index lost 4.21 per cent due to US recession fears, investors found comfort in the pharma sector, which was spared harsh treatment in the sweeping tariffs announced by US President